NON-TYPE 2 SEVERE ASTHMA DIAGNOSTICS AND MANAGEMENT

Abstract

It is known that type-2 inflammation-driven asthma, which includes the eosinophilic phenotype, is present in over two-thirds of patients with severe asthma and is typically characterized by elevated levels of type-2 inflammatory biomarkers, including blood eosinophils, serum IgE and fractional exhaled nitric oxide. Conversely, approximately one-third of patients with severe asthma do not present with increased type-2 inflammation. Most pharmaceutical therapies are for severe type-2 asthma (eosinophilic phenotype), including several biologics approved for use. Unfortunately, there are currently no approved treatments for severe asthma of non-2 type (for neutrophilic and paucigranulocytic).